Agenus (AGEN)

• Market cap: $146M
• 1 day: 0.44%
• 5 days: -2.56%
• 1 month: 0.88%
• 3 months: 2.24%
• 6 months: 164.16%
• Year to date: 47.9%
• 1 year: -24.46%
• 5 years: -95.51%
• 10 years: -96.44%
• Sector: Healthcare
• Industry: Biotechnology

About: Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).

Employees: 316

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

219% more capital invested

Capital invested by funds: $12.8M [Q1] → $40.7M (+$28M) [Q2]

18% more first-time investments, than exits

New positions opened: 33 | Existing positions closed: 28

5% more funds holding

Funds holding: 87 [Q1] → 91 (+4) [Q2]

0.99% less ownership

Funds ownership: 33.51% [Q1] → 32.52% (-0.99%) [Q2]

2% less call options, than puts

Call options by funds: $1.51M | Put options by funds: $1.54M

32% less repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 28

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $23
• Avg. target: $23
• High target: $23

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Emily Bodnar

$23

Buy Reiterated

10 Sep 2025